Aclarion, Inc. (ACON)
NASDAQ: ACON · Real-Time Price · USD
0.216
+0.027 (14.19%)
Oct 24, 2024, 4:00 PM EDT - Market closed
Aclarion Revenue
Aclarion had revenue of $10.97K in the quarter ending June 30, 2024, a decrease of -35.74%. This brings the company's revenue in the last twelve months to $53.95K, down -35.23% year-over-year. In the year 2023, Aclarion had annual revenue of $75.40K with 24.75% growth.
Revenue (ttm)
$53.95K
Revenue Growth
-35.23%
P/S Ratio
13.01
Revenue / Employee
$8,991
Employees
6
Market Cap
2.17M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 75.40K | 14.96K | 24.75% |
Dec 31, 2022 | 60.44K | 152.00 | 0.25% |
Dec 31, 2021 | 60.29K | 11.64K | 23.93% |
Dec 31, 2020 | 48.65K | 21.76K | 80.88% |
Dec 31, 2019 | 26.90K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
cbdMD | 20.64M |
NanoVibronix | 3.37M |
Tenon Medical | 3.37M |
Tivic Health Systems | 1.11M |
Helius Medical Technologies | 594.00K |
60 Degrees Pharmaceuticals | 441.26K |
FOXO Technologies | 155.00K |
ACON News
- 14 days ago - Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit - GlobeNewsWire
- 27 days ago - Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes - GlobeNewsWire
- 5 weeks ago - PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology - GlobeNewsWire
- 6 weeks ago - Aclarion Provides Corporate Update on Nociscan AI Technology Milestones - GlobeNewsWire
- 6 weeks ago - Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial - GlobeNewsWire
- 7 weeks ago - Aclarion Launches Surgeon Partnership to Apply Nociscan's AI Technology to Personal Injury and Workers Compensation Market - GlobeNewsWire
- 2 months ago - Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey - GlobeNewsWire
- 2 months ago - Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan's AI Generated Biomarker Data Changes Surgical Treatment Plans - GlobeNewsWire